<br>高载药量纳米药物：进展、现状与前景。,International Journal of Nanomedicine

当前位置： X-MOL 学术 › Int. J. Nanomed. › 论文详情

Our official English website, www.x-mol.net, welcomes your feedback! (Note: you will need to create a separate account there.)

高载药量纳米药物：进展、现状与前景。
International Journal of Nanomedicine ( IF 6.6 ) Pub Date : 2017-05-31 , DOI: 10.2147/ijn.s132780
Shihong Shen ₁ , Youshen Wu ₁ , Yongchun Liu ₁ , Daocheng Wu ₁

Affiliation

借助或不借助载体材料将药物分子转化为纳米颗粒或赋予纳米结构被称为“纳米药物”，可以克服游离药物的一些固有缺点，如水溶性差、药物剂量高、药物半衰期短等体内。然而，大多数现有的纳米药物都存在载药量低（通常小于10%）且载体材料较多的缺点。对于静脉给药，载体材料的大量使用可能会导致全身毒性，给患者带来额外的材料降解、代谢和排泄负担。因此，在保证治疗效果和功能的前提下，减少或避免使用载体材料是解决这些问题的一种有前景的替代途径。近年来，载药量高于10%的高载药量纳米药物越来越受到人们的关注。根据纳米药物的制备策略，高载药量纳米药物主要分为四大类：以惰性多孔材料为载体的纳米药物、以药物为部分载体的纳米药物、无载体纳米药物以及遵循利基和复合策略的纳米药物。迄今为止，现有的高载药量纳米药物大多属于第一类，很少有研究关注其他类。在这篇综述中，我们调查了高载药量纳米药物的研究现状，并详细讨论了其制备策略的特点和最佳方案。我们还指出了高载药量纳米药物的不足和发展方向。我们预计高载药量纳米药物将在药物递送系统领域占据重要地位，并希望为高载药量纳米药物的发展提出新的视角。

"点击查看英文标题和摘要"

High drug-loading nanomedicines: progress, current status, and prospects.

Drug molecules transformed into nanoparticles or endowed with nanostructures with or without the aid of carrier materials are referred to as "nanomedicines" and can overcome some inherent drawbacks of free drugs, such as poor water solubility, high drug dosage, and short drug half-life in vivo. However, most of the existing nanomedicines possess the drawback of low drug-loading (generally less than 10%) associated with more carrier materials. For intravenous administration, the extensive use of carrier materials might cause systemic toxicity and impose an extra burden of degradation, metabolism, and excretion of the materials for patients. Therefore, on the premise of guaranteeing therapeutic effect and function, reducing or avoiding the use of carrier materials is a promising alternative approach to solve these problems. Recently, high drug-loading nanomedicines, which have a drug-loading content higher than 10%, are attracting increasing interest. According to the fabrication strategies of nanomedicines, high drug-loading nanomedicines are divided into four main classes: nanomedicines with inert porous material as carrier, nanomedicines with drug as part of carrier, carrier-free nanomedicines, and nanomedicines following niche and complex strategies. To date, most of the existing high drug-loading nanomedicines belong to the first class, and few research studies have focused on other classes. In this review, we investigate the research status of high drug-loading nanomedicines and discuss the features of their fabrication strategies and optimum proposal in detail. We also point out deficiencies and developing direction of high drug-loading nanomedicines. We envision that high drug-loading nanomedicines will occupy an important position in the field of drug-delivery systems, and hope that novel perspectives will be proposed for the development of high drug-loading nanomedicines.

更新日期：2019-11-01

点击分享查看原文

点击收藏

公开下载

阅读更多本刊新发论文本刊介绍/投稿指南